Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends
New

LPTX
Leap Therapeutics Inc
stock NASDAQ

At Close
5/20/2022 3:59:54 PM EDT
1.17USD-3.306%(-0.04)538,930
0.9440Bid   1.18Ask   0.24Spread IEX
Pre-market
1969-12-31
0.00USD-100.000%(-1.21)0
After-hours
1969-12-31
0.00USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
103.333M
Headquarters
Cambridge, Massachusetts, USA
Industry
Biotechnology
Next Earnings
2022-08-12 (82d)
Related
PDLIPIRSXLV
Jan 31, 2022
07:11AM EST  Leica Biosystems , Leap Therapeutics Partner On Companion Diagnostic To Advance Care For Cancer Patients   RTTNews
07:01AM EST  Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to   PR Newswire
Jan 24, 2022
07:01AM EST  Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference   PR Newswire
Jan 19, 2022
07:40AM EST  The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data   Benzinga
Jan 18, 2022
05:02PM EST  Leap Therapeutics To Present New Data From DisTinGuish Study Of DKN-01 Plus Tislelizumab At The ASCO GI Cancers Symposium   Benzinga
More News
Stats
Avg. Vol. 10 Day
1,275,805
Avg. Vol. 30 Day
870,375
Employees
36
Market Cap
103,332,591
Shares Out.
88,318,454
Float
63,908,116
On/Off Exchange
46%/54%
6 Month Beta
2.12
1 Year Beta
1.69
2 Year Beta
1.23
3 Year Beta
1.06
52 Week Low
0.92
52 Week High
4.17
SMA50
1.45
SMA200
2.11
1 Week
-10.69%
1 Month
-20.41%
3 Month
-42.37%
6 Month
-45.07%
1 Year
-27.78%
2 Year
-45.07%
5 Year
-83.29%
Profile
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

LPTX Stock Summary

Leap Therapeutics Inc (NASDAQ:LPTX) stock price today is $1.17, and today's volume is 538,930. LPTX is down -3.306% today. The 30 day average volume is 870,375. LPTX market cap is 103.333M with 88,318,454 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter @chartexchange_
© 2020 - 2022 ChartExchange LLC